Literature DB >> 23345488

Gitelman or Bartter type 3 syndrome? A case of distal convoluted tubulopathy caused by CLCNKB gene mutation.

António José Cruz1, Alexandra Castro.   

Abstract

A 32-year-old woman with no significant medical history was sent to our consultation due to hypokalaemia (<3.0 mmol/l). Her main complaints were longstanding polyuria and nocturia. Physical examination was normal. Basic investigations showed normal renal function, low serum potassium (2.7 mmol/l) and magnesium (0.79 mmol/l), metabolic alkalosis (pH 7.54; bicarbonate 32.5 mmol/l), elevated urinary potassium (185 mmol/24 h) and normal urinary calcium (246 mg/24 h). Thiazide test revealed blunted response. Chronic vomiting and the abuse of diuretics were excluded. Genetic tests for SLC12A3 gene mutation described in Gitelman syndrome (GS) came negative. CLCNKB gene mutation analysis present in both GS and Bartter (BS) type 3 syndromes was positive. The patient is now being treated with potassium and magnesium oral supplements, ramipril and spironolactone with stable near-normal potassium and magnesium levels. This article presents the case of a patient with hypokalaemia caused by CLCNKB gene mutation hard to categorise as GS or BS type 3.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345488      PMCID: PMC3604527          DOI: 10.1136/bcr-2012-007929

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Bartter syndrome type 3: an unusual cause of nephrolithiasis.

Authors:  Giacomo Colussi; Maria Elisabetta De Ferrari; Silvana Tedeschi; Silvia Prandoni; Marie Louise Syrén; Giovanni Civati
Journal:  Nephrol Dial Transplant       Date:  2002-03       Impact factor: 5.992

Review 2.  Bartter's and Gitelman's syndromes: their relationship to the actions of loop and thiazide diuretics.

Authors:  Robert J Unwin; Giovambattista Capasso
Journal:  Curr Opin Pharmacol       Date:  2006-02-20       Impact factor: 5.547

Review 3.  Hypokalemia.

Authors:  F J Gennari
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

4.  A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes.

Authors:  Israel Zelikovic; Raymonde Szargel; Ali Hawash; Valentina Labay; Ihab Hatib; Nadine Cohen; Farid Nakhoul
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

5.  Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome.

Authors:  Martin Konrad; Martin Vollmer; Henny H Lemmink; Lambertus P W J VAN DEN Heuvel; Nikola Jeck; Rosa Vargas-Poussou; Alicia Lakings; Rainer Ruf; Georges Deschênes; Corinne Antignac; Lisa Guay-Woodford; Nine V A M Knoers; Hannsjörg W Seyberth; Delphine Feldmann; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2000-08       Impact factor: 10.121

Review 6.  Salt handling in the distal nephron: lessons learned from inherited human disorders.

Authors:  Nikola Jeck; Karl P Schlingmann; Stephan C Reinalter; Martin Kömhoff; Melanie Peters; Siegfried Waldegger; Hannsjörg W Seyberth
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-04       Impact factor: 3.619

Review 7.  An approach to the patient with severe hypokalaemia: the potassium quiz.

Authors:  J H M Groeneveld; Y W J Sijpkens; S-H Lin; M R Davids; M L Halperin
Journal:  QJM       Date:  2005-03-10

8.  A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain.

Authors:  Juan Rodríguez-Soriano; Alfredo Vallo; Gustavo Pérez de Nanclares; José Ramón Bilbao; Luis Castaño
Journal:  Pediatr Nephrol       Date:  2005-05-05       Impact factor: 3.714

Review 9.  Bartter's and Gitelman's syndromes: from gene to clinic.

Authors:  Maarten Naesens; Paul Steels; René Verberckmoes; Yves Vanrenterghem; Dirk Kuypers
Journal:  Nephron Physiol       Date:  2004

10.  A thiazide test for the diagnosis of renal tubular hypokalemic disorders.

Authors:  Giacomo Colussi; Alberto Bettinelli; Silvana Tedeschi; Maria Elisabetta De Ferrari; Marie Louise Syrén; Nicolò Borsa; Camilla Mattiello; Giorgio Casari; Mario Giovanni Bianchetti
Journal:  Clin J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 8.237

View more
  8 in total

Review 1.  Pathophysiology and clinical presentations of salt-losing tubulopathies.

Authors:  Hannsjörg W Seyberth
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

2.  Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations.

Authors:  Amar Al Shibli; Hassib Narchi
Journal:  World J Methodol       Date:  2015-06-26

3.  The Bartter-Gitelman Spectrum: 50-Year Follow-up With Revision of Diagnosis After Whole-Genome Sequencing.

Authors:  Mark Stevenson; Alistair T Pagnamenta; Heather G Mack; Judith Savige; Edoardo Giacopuzzi; Kate E Lines; Jenny C Taylor; Rajesh V Thakker
Journal:  J Endocr Soc       Date:  2022-05-15

4.  Potassium Homeostasis, Oxidative Stress, and Human Disease.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  Int J Clin Exp Physiol       Date:  2017

5.  Mixed Bartter-Gitelman syndrome: an inbred family with a heterogeneous phenotype expression of a novel variant in the CLCNKB gene.

Authors:  Amar Al-Shibli; Madinah Yusuf; Issam Abounajab; Patrick J Willems
Journal:  Springerplus       Date:  2014-02-18

6.  A case of Gitelman syndrome: our experience with a patient treated in clinical practice on a local island.

Authors:  Takashi Chinen; Eiji Saeki; Takayasu Mori; Eisei Sohara; Shinichi Uchida; Tetsu Akimoto
Journal:  J Rural Med       Date:  2019-11-20

Review 7.  Physiological Processes Modulated by the Chloride-Sensitive WNK-SPAK/OSR1 Kinase Signaling Pathway and the Cation-Coupled Chloride Cotransporters.

Authors:  Adrián Rafael Murillo-de-Ozores; María Chávez-Canales; Paola de Los Heros; Gerardo Gamba; María Castañeda-Bueno
Journal:  Front Physiol       Date:  2020-10-20       Impact factor: 4.566

8.  Bartter syndrome with long-term follow-up: a case report.

Authors:  Xueling Wu; Gang Yang; Shiyu Chen; Min Tang; Shan Jian; Fuhui Chen; Xiulin Wu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.